The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders

Current Topics in Medicinal Chemistry

Volumn 15, Issue 21, 2015, Pages 2233-2238

  Cutler, Roy G ^a   Camandola, Simonetta ^a   Malott, Kelli F ^a   Edelhauser, Maria A ^a   Mattson, Mark P ^a,b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Antioxidant; Caffeine; Neurodegeneration; Theobromine; Urate Oxidase; Uric acid

Indexed keywords

SUPEROXIDE DISMUTASE; URIC ACID; CAFFEINE; THEOBROMINE; THEOPHYLLINE;

ANTIOXIDANT ACTIVITY; APE; ARTICLE; DEGENERATIVE DISEASE; DRUG TARGETING; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HYPERURICEMIA; NEUROPROTECTION; NONHUMAN; SURVIVAL; AGING; ANIMAL; BLOOD; DIETARY SUPPLEMENT; MAMMAL; METABOLISM; NEURODEGENERATIVE DISEASES;

AGING; ANIMALS; CAFFEINE; DIETARY SUPPLEMENTS; HUMANS; MAMMALS; NEURODEGENERATIVE DISEASES; THEOBROMINE; THEOPHYLLINE; URIC ACID;

EID: 84939810704     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150610143234     Document Type: Article

References (84)

1. [1] Church, W.H.; Ward, V.L. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect of dopamine oxidation. Brain Res. Bull., 1994, 33, 419-425.
2. [2] Toncev, G.; Millicic, B.; Toncev, S.; Samardzic, G. Serum uric acid in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur. J. Neuro., 2002, 9, 221-226.
3. [3] Kim, T.S.; Pae, C.U.; Yoon, S.J.; Jang, W.Y.; Lee, N.J.; Kim, J.J.; Lee, S.J.; Lee, C.; Paik, I.H.; Lee, C.U. Decreased plasma antioxidants in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry, 2006, 21, 344-348.
4. [4] Keizman, D.; Ish-Shalom, M.; Berliner, S.; Maimon, N.; Vered, Y.; Artamonov, I.; Tsehori, J.; Nefussy, B.; Drory, V.E. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J. Neurol. Sci., 2009, 285, 95–99.
5. [5] Euser, S.M.; Hofman, A.; Westendorp, R.G.; Breteler, M.M. Serum uric acid and cognitive function and dementia. Brain, 2009, 132, 377-382.
6. [6] Du, Y.; Chen, C.P.; Tseng, C.Y.; Eisenberg, Y.; Firestein, B.L. Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia, 2007, 55(5), 463-472.
7. [7] Cipriani, S.; Desjardins, C.A.; Burdett, T.C.; Xu, Y.; Xu, K.; Schwarzschild, M.A. Protection of dopaminergic cells by urate requires its accumulation in astrocytes. J Neurochem. 2012, 123(1),172-181.
8. [8] Nakagawa, T.; Hu, H.; Zharikov, S.; Tuttle, K.R.; Short, R.A.; Glushakova, O.; Ouyang, X.; Feig, D.I.; Block, E.R.; Herrera-Acosta, J.; Patel, J.M.; Johnson, R.J. A causal role for uric acid in fructose-induced metabolic syndrome. Am. J Physiol Renal Physiol. 2006, 290(3), F625-631.
9. [9] Soltani, Z.; Rasheed, K.; Kapusta, D.R.; Reisin, E. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep. 2013, 15(3), 175-181.
10. [10] Zhao, G.; Huang, L.; Song, M.; Song, Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis, 2013, 231(1), 61-68.
11. [11] Lin, J.; Yang, R.; Tarr, P.T.; Wu, P.H.; Handschin, C.; Li, S.; Yang, W.; Pei, L.; Uldry, M.; Tontonoz, P.; Newgard, C.B.; Spiegelman, B.M. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell, 2005, 120(2), 261-273.
12. [12] Lanaspa, M.A.; Cicerchi, C.; Garcia, G.; Li, N.; Roncal-Jimenez, C.A.; Rivard, C.J.; Hunter, B.; Andrés-Hernando, A.; Ishimoto, T.; Sánchez-Lozada, L.G.; Thomas, J.; Hodges, R.S.; Mant, C.T.; Johnson, R.J. Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver. PLoS One, 2012, 7(11), e48801.
13. [13] Nieto, F.J.; Iribarren, C.; Gross, M.D.; Comstock, G.W.; Cutler, R.G. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis, 2000, 148(1), 131-139.
14. [14] Rock, K.L.; Kataoka, H.; Lai, J.J. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol., 2013, 9(1), 13-23.
15. [15] Pardo, M.; Budick-Harmelin, N.; Tirosh, B.; Tirosh, O. Antioxidant defense in hepatic ischemia-reperfusion injury is regulated by damage-associated molecular pattern signal molecules. Free Radic Biol Med. 2008, 45(8), 1073-1083.
16. [16] Parkinson, F.E.; Sinclair, C.J.; Othman, T.; Haughey, N.J.; Geiger, J.D. Differences between rat primary cortical neurons and astrocytes in purine release evoked by ischemic conditions. Neuropharmacology, 2002, 43(5), 836-846.
17. [17] Hayashi, S.; Fujiwara, S.; Noguchi, T. Evolution of urate-degrading enzymes in animal peroxisomes. Cell Biochem. Biophys., 2000, 32,123–129.
18. [18] Nakamura, Y.; Ogura, M.; Ogura, K.; Tanaka, D.; Inagaki, N. SIRT5 deacetylates and activates urate oxidase in liver mitochondria of mice. FEBS Lett., 2012, 586, 4076-4081.
19. [19] Alvarez-Lario, B.; Macarrón-Vicente, J. Is there anything good in uric acid? QJM., 2011, 104(12), 1015-1024.
20. [20] Xu, P.; LaVallee, P.A.; Lin, J.J.; Hoidal, J.R. Characterization of proteins binding to E-box/Ku86 sites and function of Ku86 in transcriptional regulation of the human xanthine oxidoreductase gene. J Biol Chem., 2004, 279(16), 16057-16063.
21. [21] Oda, M.; Satta, Y.; Takenaka, O.; Takahata, N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol. Biol. Evol., 2002, 19, 640–653.
22. [22] Wu, X.; Muzny, DM.; Lee, CC.; Caskey, CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J. Mol. Evol., 1992, 34, 78–84.
23. [23] Bobulescu, I.A.; Moe, O.W. Renal transport of uric acid: evolving concepts and uncertainties. Adv. Chronic Kidney Dis., 2012, 19, 358-371.
24. [24] Watanabe, S.; Kang, D.H.; Feng, L.; Nakagawa, T.; Kanellis, J.; Lan, H.; Mazzali, M.; Johnson, R.J. Uric acid, hominoid evolution and the pathogenesis of salt-sensitivity. Hypertension, 2002, 40, 355–360.
25. [25] Ames, B.N.; Cathcart, R.; Schwiers, E.; Hochstein, P. Uric acid provides an antioxidant defense in human against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl. Acad. Sci. U.S.A., 1981, 78, 6858–6862.
26. [26] Sydenham, T. Tractatus de Podagra et Hydrope. Early History of Medicine. Health and Disease. G Kettilby: London, England,1683.
27. [27] Orowan, E. The origin of Man. Nature, 1955, 175, 683-684.
28. [28] Stetten, D.; Hearon, J.Z. Intellectual level measured by army classification battery and serum uric acid concentration. Science, 1959, 129, 1737.
29. [29] Inouye, E.; Park, K.S.; Asaka, A. Blood uric acid level and IQ: a study in twin families. Acta Genet. Med. Gemellol., 1984, 33, 237-242.
30. [30] Bloch, S.; Brackenridge, C.J. Psychological, performance and biochemical factors in medical students under examination stress. J. Psychosom. Res., 1972, 16, 25–33.
31. [31] Stevens, H.A.; Cropley, AJ.; Blatter, DP. Intellect and serum uric acid: an optimal concentration of serum urate for human learning? Soc. Biol., 1975, 22, 229-234.
32. [32] Kasl, S.V.; Brooks, G.W.; Rodgers, W.L. Serum uric acid and cholesterol in achievement behavior and motivation. I. The relationship to ability, grades, test performance and motivation. JAMA, 1970, 213, 1158-1164.
33. [33] Brooks, G.W.; Mueller, E. Serum urate concentrations among university professors; relation to drive, achievement, and leadership. JAMA, 1966, 195, 415-418
34. [34] Sutin, A.R.; Cutler, R.G.; Camandola, S.; Uda, M.; Feldman, N.H.; Cucca, F.; Zonderman, A.B.; Mattson, M.P.; Ferrucci, L.; Schlessinger, D.; Terracciano, A. Impulsivity is associated with uric acid: evidence from humans and mice. Biol. Psychiatry. 2014, 75, 31-37.
35. [35] Barrera, C.M.; Ruiz, Z.R.; Dunlap, W.P. Uric acid: a participating factor in the symptoms of hyperactivity. Biol. Psychiatry, 1988, 24, 344–347.
36. [36] Jossa, F.; Farinaro, E.; Panico, S.; Krogh, V.; Celentano, E.; Galasso, R.; Mancini, M.; Trevisan, M. Serum uric acid and hypertension: the Olivetti heart study. J. Hum. Hypertens., 1994, 8, 677-681.
37. [37] Freedman, D.S.; Williamson, D.F.; Gunter, E.W.; Byers, T. Relation of uric acid to mortality and ischemic heart disease. The NHANES I epidemiologic follow-up study. Am. J. Epidemiol., 1995, 141, 637-644.
38. [38] Heinig, M.; Johnson, R.J. Role of uric acid in hypertension, renal disease and metabolic syndrome. Cleve. Clin. J. Med. 2006, 73, 1059-1064.
39. [39] Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. U S A., 1998, 95, 675-680.
40. [40] Drulović, J.; Dujmović, I.; Stojsavljević, N.; Mesaros, S.; Andjelković, S.; Miljković, D.; Perić, V, Dragutinović, G.; Marinković, J.; Lević, Z.; Mostarica Stojković, M. Uric acid levels in sera from patients with multiple sclerosis. J. Neurol., 2001, 248, 121-126.
41. [41] Toncev, G. Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis. Vojnosanit Pregl., 2006, 63, 879-882.
42. [42] Markowitz, C.E.; Spitsin, S.; Zimmerman, V.; Jacobs, D.; Udupa, J.K.; Hooper, D.C.; Koprowski, H. The treatment of multiple sclerosis with inosine. J. Altern. Complement. Med., 2009, 15, 619-625.
43. [43] Paganoni, S.; Zhang, M.; Quiroz Zárate, A.; Jaffa, M.; Yu, H.; Cudkowicz, M.E.; Wills, A.M. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J. Neurol., 2012, 259, 1923-1928.
44. [44] Kataoka, H.; Kiriyama, T.; Kobayashi, Y.; Horikawa, H.; Ueno, S. Clinical outcomes and serum uric acid levels in elderly patients with amyotrophic lateral sclerosis aged ≥ 70 years. Am. J. Neurodegener. Dis., 2013, 2, 140-144.
45. [45] Atassi, N.; Berry, J.; Shui, A.; Zach, N.; Sherman, A.; Sinani, E.; Walker, J.; Katsovskiy, I.; Schoenfeld, D.; Cudkowicz, M.; Leitner, M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology, 2014, 83, 1719-1725.
46. [46] Auinger, P.; Kieburtz, K.; McDermott, M.P. The relationship between uric acid levels and Huntington's disease progression. Mov. Disord., 2010, 25, 224-228.
47. [47] de Lau, L.M.; Koudstaal, P.J.; Hofman, A.; Breteler, M.M. Serum uric acid levels and the risk of Parkinson disease. Ann, Neurol., 2005, 58, 797-800.
48. [48] Ascherio, A.; LeWitt, P.A.; Xu, K.; Eberly, S.; Watts, A.; Matson, W.R.; Marras, C.; Kieburtz, K.; Rudolph, A.; Bogdanov, M.B.; Schwid, S.R.; Tennis, M.; Tanner, C.M.; Beal, M.F.; Lang, A.E.; Oakes, D.; Fahn, S.; Shoulson, I.; Schwarzschild, M.A.; Parkinson Study Group DATATOP Investigators. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch, Neurol., 2009, 66, 1460-1468.
49. [49] Annanmaki, T.; Pessala-Driver, A.; Hokkanen, L.; Murros K. Uric acid associates with cognition in Parkinson's disease. Parkinsonism Relat. Disord., 2008, 14, 576-578.
50. [50] Gao, X.; Chen, H.; Choi, H.K.; Curhan, G.; Schwarzschild, M.A.; Ascherio, A. Diet, urate, and Parkinson's disease risk in men. Am. J. Epidemiol., 2008, 167, 831-838.
51. [51] Facheris, M.F.; Hicks, A.A.; Minelli, C.; Hagenah, J.M.; Kostic, V.; Campbell, S.; Hayward, C.; Volpato, C.B.; Pattaro, C.; Vitart, V.; Wright, A.; Campbell, H.; Klein, C.; Pramstaller, P.P. Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson's disease. J. Mol. Neurosci., 2011, 43, 246-250.
52. [52] Simon, K.C.; Eberly, S.; Gao, X.; Oakes, D.; Tanner, C.M.; Shoulson, I.; Fahn, S.; Schwarzschild, M.A.; Ascherio, A.; Parkinson Study Group. Mendelian randomization of serum urate and parkinson disease progression. Ann. Neurol., 2014, 76, 862-868.
53. [53] Schwarzschild, M.A.; Macklin, E.A.; Ascherio, A.; Parkinson Study Group SURE-PD Investigators. Urate and neuroprotection trials. Lancet Neurol., 2014, 13, 758.
54. [54] Maesaka, J.K.; Wolf-Klein, G.; Piccione, J.M.; Ma, C.M. Hypouricemia, abnormal renal tubular urate transport, and plasma natriuretic factor(s) in patients with Alzheimer's disease. J. Am. Geriatr. Soc,. 1993, 41, 501-506.
55. [55] Rinaldi, P.; Polidori, M.C.; Metastasio, A.; Mariani, E.; Mattioli, P.; Cherubini, A.; Catani, M.; Cecchetti, R.; Senin, U.; Mecocci, P. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol. Aging, 2003, 24, 915-919.
56. [56] Lu, N.; Dubreuil, M.; Zhang, Y.; Neogi, T.; Rai, S.K.; Ascherio, A.; Hernán, M.A.; Choi, H.K. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. Ann. Rheum. Dis., 2015 Mar 4. pii: annrheumdis-2014-206917.
57. [57] Euser, S.M.; Hofman, A.; Westendorp, R.G.; Breteler, M.M. Serum uric acid and cognitive function and dementia. Brain, 2009, 132, 377-382.
58. [58] Irizarry, M.C.; Raman, R.; Schwarzschild, M.A.; Becerra, L.M.; Thomas, R.G.; Peterson, R.C.; Ascherio, A.; Aisen, P.S. Plasma urate and progression of mild cognitive impairment. Neurodegener. Dis., 2009, 6, 23–28.
59. [59] Yu, Z.F.; Bruce-Keller, A.J.; Goodman, Y.; Mattson, M.P. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J. Neurosci. Res., 1998, 53, 613-625.
60. [60] Haberman, F.; Tang, S.C.; Arumugam, T.V.; Hyun, D.H.; Yu, Q.S.; Cutler, R.G.; Guo, Z.; Holloway, H.W.; Greig, N.H.; Mattson, M.P. Soluble neuroprotective antioxidant uric acid analogs ameliorate ischemic brain injury in mice. Neuromolecular Med., 2007, 9, 315-323.
61. [61] Romanos, E.; Planas, A.M.; Amaro, S.; Chamorro, A. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J. Cereb. Blood Flow Metab., 2007, 27, 14-20.
62. [62] Chamorro, A.; Amaro, S.; Castellanos, M.; Segura, T.; Arenillas, J.; Martí-Fábregas, J.; Gállego, J.; Krupinski, J.; Gomis, M.; Cánovas, D.; Carné, X.; Deulofeu, R.; Román, LS.; Oleaga, L.; Torres, F.; Planas A.M.; URICO-ICTUS Investigators. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomized, double-blind phase 2b/3 trial. Lancet Neurol., 2014, 13, 453-460.
63. [63] Du, Y.; Chen, C.P.; Tseng, C.Y.; Eisenberg, Y.; Firestein, B.L. Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia, 2007, 55, 463-472.
64. [64] Beaudoin, M.S.; Graham, T.E. Methylxanthines and human health: epidemiological and experimental evidence. Hand Exp. Pharmacol., 2011, 200, 509-548.
65. [65] Franco, R.; Oñatibia-Astibia, A.; Martínez-Pinilla, E. Health benefits of methylxanthines in cacao and chocolate. Nutrients, 2013, 5, 4159-4173.
66. [66] Mattson, M.P. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med., 2003, 3, 65-94.
67. [67] Pardo, C.A.; Xu, Z.; Borchelt, D.R.; Price, D.L.; Sisodia, S.S.; Cleveland, D.W. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Natl Acad Sci U S A., 1995, 92(4), 954-958.
68. [68] Oury, T.D.; Card, J.P.; Klann, E. Localization of extracellular superoxide dismutasein adult mouse brain. Brain Res., 1999, 850(1-2), 96-103.
69. [69] Hink, H.U.; Santanam, N.; Dikalov, S.; McCann, L.; Nguyen, A.D.; Parthasarathy, S.; Harrison, D.G.; Fukai, T. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol., 2002, 22(9), 1402-1408.
70. [70] Davies, K.J.; Sevanian, A.; Muakkassah-Kelly, S.F.; Hochstein, P. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem. J., 1986, 235, 747-754.
71. [71] Obukuro, K.; Nobunaga, M.; Takigawa, M.; Morioka, H.; Hisatsune, A.; Isohama, Y.; Shimokawa, H.; Tsutsui, M.; Katsuki, H. Nitric oxide mediates selective degeneration of hypothalamic orexin neurons through dysfunction of protein disulfideisomerase. J Neurosci., 2013, 33(31), 12557-12568.
72. [72] Squadrito, G.L.; Cueto, R.; Splenser, A.E.; Valavanidis, A.; Zhang, H.; Uppu, R.M.; Pryor, W.A. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch. Biochem. Biophys., 2000, 376(2), 333-337.
73. [73] Liu, D.H.; Yuan, F.G.; Hu, S.Q.; Diao, F.; Wu, Y.P.; Zong, Y.Y.; Song, T.; Li, C.; Zhang, G.Y. Endogenous nitric oxide induces activation of apoptosis signal-regulating kinase 1 via S-nitrosylation in rat hippocampus during cerebral ischemia-reperfusion. Neuroscience, 2013, 229, 36-48.
74. [74] Kim, K. M.; Henderson, G. N.; Frye, R. F.; Galloway, C. D.; Brown, N. J.; Segal, M. S.; Imaram, W.; Angerhofer, A.; Johnson, R.J. Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry. Journal of chromatography B, Analytical technologies in the biomedical and life sciences, 2009, 877(1-2), 65-70.
75. [75] Robinson, K. M.; Morre, J. T.; Beckman, J. S. Triuret: a novel product of peroxynitrite-mediated oxidation of urate. Archives of biochemistry and biophysics, 2004, 423(1), 213-217.
76. [76] Ruderman, N. B.; Park, H.; Kaushik, V. K.; Dean, D.; Constant, S.; Prentki, M.; Saha, A.K. AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta physiologica Scandinavica, 2003, 178(4), 435-442.
77. [77] Lanaspa, M.A.; Sanchez-Lozada, L.G.; Cicerchi, C.; Li, N.; Roncal-Jimenez, C.A.; Ishimoto, T.; Le, M.; Garcia, G.E.; Thomas, J.B.; Rivard, C.J.; Andres-Hernando, A.; Hunter, B.; Schreiner, G.; Rodriguez-Iturbe, B.; Sautin, Y.Y.; Johnson, R.J. Uric acid s timulatesfructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS One, 2012, 7(10):e47948.
78. [78] Aoyama, K.; Matsumura, N.; Watabe, M.; Wang, F.; Kikuchi- Utsumi, K.; Nakaki, T. Caffeine and uric acid mediate glutathione synthesis for neuroprotection. Neuroscience, 2011, 181, 206-215.
79. [79] Zhang, N.; Shu, H.Y.; Huang, T.; Zhang, Q.L.; Li, D.; Zhang, G.Q.; Peng, X.Y.; Liu C.F.; Luo W.F.; Hu L.F. Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity. PLoS One, 2014, 9:e100286.
80. [80] Odden, M.C.; Amadu, A.R.; Smit, E.; Lo, L.; Peralta, C.A. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. Am J Kidney Dis. 2014, 64(4), 550-557.
81. [81] Haskó, G.; Sitkovsky, M.V.; Szab,ó C. Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci., 2004, 25, 152-157.
82. [82] Parkinson Study Group SURE-PD Investigators; Schwarzschild, M.A.; Ascherio, A.; Beal, M.F.; Cudkowicz, M.E.; Curhan, G.C.; Hare, J.M.; Hooper, D.C.; Kieburtz, K.D.; Macklin, E.A.; Oakes, D.; Rudolph, A.; Shoulson, I.; Tennis, M.K.; Espay, A.J.; Gartner, M.; Hung, A.; Bwala, G.; Lenehan, R.; Encarnacion, E.; Ainslie, M.; Castillo, R.; Togasaki, D.; Barles, G.; Friedman, J.H.; Niles, L.; Carter, J.H.; Murray, M.; Goetz, C.G.; Jagli, J.; Ahmed, A.; Russell, D.S.; Cotto, C.; Goudrea, J.L.; Russell, D.; Parashos, S.A.; Ede, P.; Saint-Hilaire, M.H.; Thomas, C.A.; James, R.; Stacy, M.A.; Johnson, J.; Gauger, L.; Antonelle de Marcaid, J.; Thurlow, S.; Isaacson, S.H.; Carvajal, L.; Rao, J.; Cook, M.; Hope-Porche, C.; McClurg, L.; Grasso, D.L.; Logan, R.; Orme, C.; Ross, T.; Brocht, A.F.; Constantinescu, R.; Sharma, S.; Venuto, C.; Weber, J.; Eaton, K. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol., 2014, 71, 141-150.
83. [83] Coolen, E.J.; Arts, I.C.; Bekers, O.; Vervaet, C.; Bast, A.; Dagnelie, P.C. Oral bioavailability of ATP after prolonged administration. Br. J. Nutr., 2011, 105, 357-366.
84. [84] Arts, I.C.; Coolen, E.J.; Bours, M.J.; Huyghebaert, N.; Stuart, M.A.; Bast, A.; Dagnelie, P.C. Adenosine 5'-triphosphate (ATP) supplements are not orally bioavailable: a randomized, placebocontrolled cross-over trial in healthy humans. J. Int. Soc. Sports Nutr., 2012, 9,16